Journal
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
Volume 150, Issue 1, Pages 17-21Publisher
MOSBY-ELSEVIER
DOI: 10.1016/j.jaci.2022.05.008
Keywords
Approved vaccines; variants of concern; SARS-CoV-2; COVID-19; preclinical vaccines; side effects; vaccine hesitancy; vaccine strategies
Categories
Funding
- NIH/NIAID [1R21 AI158044-01]
Ask authors/readers for more resources
This review examines the path of vaccine discovery for COVID-19 and discusses challenges and opportunities. It also covers emerging mutations within the SARS-CoV-2 spike protein and other issues that need to be addressed.
In the years since the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic began and spread across the globe, lessons have been learned about the challenges and opportunities that a pandemic brings to humankind. Researchers have produced many vaccines at unprecedented speed to protect people, but they have also been cognizant of the challenges presented by a new and unexpected infectious disease. The scope of this review is to examine the path of vaccine discovery so far and identify potential targets. Here, we provide insight into the leading vaccines and their advantages and challenges. We discuss the emerging mutations within the SARS-CoV-2 spike protein and other issues that need to be addressed to overcome coronavirus disease 2019 (COVID-19) completely. Future research is needed to develop a cheap, temperature-stable vaccine providing long-term immunity that protects the upper respiratory tract.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available